本页面由Tiger Trade Technology Pte. Ltd.提供服务

Artiva Biotherapeutics, Inc.

11.52
+0.59005.40%
盘后11.680.1600+1.39%19:51 EDT
成交量:30.72万
成交额:347.10万
市值:5.63亿
市盈率:-3.59
高:11.70
开:10.83
低:10.49
收:10.93
52周最高:14.53
52周最低:2.22
股本:4,888.58万
流通股本:1,989.95万
量比:1.01
换手率:1.54%
股息:- -
股息率:- -
每股收益(TTM):-3.2084
每股收益(LYR):-3.4309
净资产收益率:-36.58%
总资产收益率:-22.34%
市净率:1.62
市盈率(LYR):-3.36

数据加载中...

2026/08/19

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/08/14

超过5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/08/10

超过5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/08/06

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2026/08/06

重要事件披露

Form 8-K - Current report
2026/07/22

重要事件披露

Form 8-K - Current report
2026/05/19

重要事件披露

Form 8-K - Current report
2026/05/18

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/05/18

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/05/18

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/05/18

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/05/18

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/05/18

超过5%披露

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
2026/05/08

重要事件披露

Form 8-K - Current report
2026/05/08

[补充]招股说明书

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
2026/05/08

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2026/05/08

重要事件披露

Form 8-K - Current report
2026/04/30

[修订]年度报告

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
2026/03/10

年度报告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2026/03/10

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans